Opendata, web and dolomites

CAN-IT-BARRIERS SIGNED

Disruption of systemic and microenvironmental barriers to immunotherapy of antigenic tumors

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CAN-IT-BARRIERS project word cloud

Explore the words cloud of the CAN-IT-BARRIERS project. It provides you a very rough idea of what is the project "CAN-IT-BARRIERS" about.

presenting    functional    mediated    tumors    immunotherapy    resistance    oncoproteins    expression    immunogenic    basis    poorly    killing    populations    multiple    ostensibly    mouse    elicit    alone    nonspecific    mostly    corollary    encode    therapeutic    genetically    attack    producing    complemented    antigen    keratinocytes    neo    efficacy    stimulatory    probe    immuno    hpv    induction    impairing    barriers    e6    ctls    lay    cancer    pharmacologically    papillomavirus    helping    lab    refractory    immune    establishing    patients    breaking    cytotoxic    adaptive    operative    infiltrating    marked    unprecedented    eliminating    therapy    overarching    expressing    systemic    cells    strategies    actionable    benefit    cancers    faceted    erect    models    expansion    spectrum    myeloid    infiltration    oncogene    orchestrating    oncogenes    immunosuppression    mechanisms    antigens    ll    barrier    types    solid    groundwork    manifestation    responsive    survival    immunotherapies    efficacious    human    hypothesis    lack    cd8    inhibit    reactive    concert    dendritic    modalities    immunosuppressive    spleen    microenvironment    lymph    priori    lies    nodes    activation    combined    tumor    frontier    expanded    tumorigenesis    circumvent    turn   

Project "CAN-IT-BARRIERS" data sheet

The following table provides information about the project.

Coordinator
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE 

Organization address
address: BATIMENT CE 3316 STATION 1
city: LAUSANNE
postcode: 1015
website: www.epfl.ch

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 2˙500˙000 €
 EC max contribution 2˙500˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-ADG
 Funding Scheme ERC-ADG
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2024-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE CH (LAUSANNE) coordinator 2˙500˙000.00

Map

 Project objective

The frontier in cancer therapy of orchestrating the immune system to attack tumors is producing unprecedented survival benefit in some patients. The corollary is lack of efficacy both in ostensibly responsive tumor types as well as others that are mostly non-responsive. The basis lies in pre-existing and adaptive resistance mechanisms that circumvent induction of tumor-reactive cytotoxic T cells (CTLs) capable of infiltrating solid tumors and eliminating cancer cells. A priori, cancers induced by expression of human papillomavirus oncogenes should be responsive to immunotherapy: these cancers encode immunogenic neo-antigens – the oncoproteins E6/7 – necessary for their manifestation. Rather, such tumors are poorly responsive to immunotherapies. Results from my lab and others using mouse models of HPV-induced cancer have established an actionable hypothesis: during tumorigenesis, such tumors erect multiple barriers to the induction, infiltration, and killing of cancer cells by tumor antigen-reactive CTLs. These include overarching systemic antigen-nonspecific immunosuppression mediated by expanded populations of myeloid cells in spleen and lymph nodes, complemented by immune response-impairing barriers operative in the tumor microenvironment. A spectrum of models will probe these barriers, genetically and pharmacologically, establishing their functional importance, alone and in concert. A major focus will be on how oncogene-expressing keratinocytes elicit a marked expansion of immunosuppressive myeloid cells in spleen and lymph nodes, and how these myeloid cells in turn inhibit development and activation of CD8 T cells and antigen-presenting dendritic cells. Then we’ll assess the therapeutic potential of barrier-breaking strategies combined with immuno-stimulatory modalities. This project will deliver new knowledge about multi-faceted barriers to immunotherapy in these refractory cancers, helping lay the groundwork for efficacious immunotherapy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CAN-IT-BARRIERS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CAN-IT-BARRIERS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

THERMONANO (2018)

Nanoassemblies for the subcutaneous self-administration of anticancer drugs

Read More  

EXTREME (2020)

The Epistemology and Ethics of Fundamentalism

Read More  

IceAGenT (2019)

Ice Age Genomic Tracking of Refugia and Postglacial Dispersal

Read More